Search research articles
Contact Us
Filters
Showing results (11-20 of 31) with videos related to
Page
of 4
Sort By:
International Journal of Molecular Sciences
|
June 13, 2025
Emerging Immunotherapy Targets in Early Drug Development
Daniel Morchón-Araujo, Greta Catani, Oriol Mirallas, et al.
Cancer Medicine
|
October 11, 2023
Selinexor for the treatment of recurrent or metastatic salivary gland tumors: Results from the GEMS-001 clinical trial
Alberto Hernando-Calvo, Eoghan Malone, Daphne Day, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 8, 2026
Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial
Glenn J Hanna, Dan P Zandberg, Deborah J Wong, et al.
Oral Oncology
|
March 29, 2023
Nutritional status associates with immunotherapy clinical outcomes in recurrent or metastatic head and neck squamous cell carcinoma patients
Alberto Hernando-Calvo, Oriol Mirallas, David Marmolejo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 11, 2025
Phase I clinical trial of the bifunctional EGFR/TGF-β fusion protein ficerafusp alfa (BCA101) alone and in combination with pembrolizumab for advanced solid tumors
Alberto Hernando-Calvo, Richard D Carvajal, Paul K Paik, et al.
Journal for Immunotherapy of Cancer
|
December 21, 2025
Integrating C-reactive protein flare and early MRI dynamics for enhanced prediction of immunotherapy response
Daniel Navarro-Garcia, Francesco Grussu, Christina Zatse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 8, 2026
Phase I trial of intravenous VCN-01 oncolytic adenovirus and durvalumab in patients with head and neck metastatic squamous cell carcinoma refractory to immunotherapy
Maria Jove, Irene Braña, Marc Oliva, et al.
The Laryngoscope
|
August 26, 2025
Prognostic Factors in Sinonasal Cancers: A Multicenter Pooled Analysis
Milica Stefanovic, Alberto Hernando-Calvo, Jesus Brenes Castro, et al.
Eclinicalmedicine
|
February 21, 2024
Impact on costs and outcomes of multi-gene panel testing for advanced solid malignancies: a cost-consequence analysis using linked administrative data
Alberto Hernando-Calvo, Paul Nguyen, Philippe L Bedard, et al.
Future Oncology (London, England)
|
March 4, 2026
Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or <i>HER2</i>-mutant solid tumors
Alison M Schram, John J Park, Antoine Italiano, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 31) with videos related to
Sort By:
Page
of 4
International Journal of Molecular Sciences
|
June 13, 2025
Emerging Immunotherapy Targets in Early Drug Development
Daniel Morchón-Araujo, Greta Catani, Oriol Mirallas, et al.
Cancer Medicine
|
October 11, 2023
Selinexor for the treatment of recurrent or metastatic salivary gland tumors: Results from the GEMS-001 clinical trial
Alberto Hernando-Calvo, Eoghan Malone, Daphne Day, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 8, 2026
Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial
Glenn J Hanna, Dan P Zandberg, Deborah J Wong, et al.
Oral Oncology
|
March 29, 2023
Nutritional status associates with immunotherapy clinical outcomes in recurrent or metastatic head and neck squamous cell carcinoma patients
Alberto Hernando-Calvo, Oriol Mirallas, David Marmolejo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 11, 2025
Phase I clinical trial of the bifunctional EGFR/TGF-β fusion protein ficerafusp alfa (BCA101) alone and in combination with pembrolizumab for advanced solid tumors
Alberto Hernando-Calvo, Richard D Carvajal, Paul K Paik, et al.
Journal for Immunotherapy of Cancer
|
December 21, 2025
Integrating C-reactive protein flare and early MRI dynamics for enhanced prediction of immunotherapy response
Daniel Navarro-Garcia, Francesco Grussu, Christina Zatse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 8, 2026
Phase I trial of intravenous VCN-01 oncolytic adenovirus and durvalumab in patients with head and neck metastatic squamous cell carcinoma refractory to immunotherapy
Maria Jove, Irene Braña, Marc Oliva, et al.
The Laryngoscope
|
August 26, 2025
Prognostic Factors in Sinonasal Cancers: A Multicenter Pooled Analysis
Milica Stefanovic, Alberto Hernando-Calvo, Jesus Brenes Castro, et al.
Eclinicalmedicine
|
February 21, 2024
Impact on costs and outcomes of multi-gene panel testing for advanced solid malignancies: a cost-consequence analysis using linked administrative data
Alberto Hernando-Calvo, Paul Nguyen, Philippe L Bedard, et al.
Future Oncology (London, England)
|
March 4, 2026
Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or <i>HER2</i>-mutant solid tumors
Alison M Schram, John J Park, Antoine Italiano, et al.
Page
of 4